Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 208320, held by Glenmark Speclt. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 208320 (Triamcinolone Acetonide), held by Glenmark Speclt, was first approved by FDA on Aug 22, 2017, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Triamcinolone Acetonide Ointment 0.1% and 0.5% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 22, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.1% · ointment;topical | Triamcinolone Acetonide | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
